Press release
Antibody Drug Conjugate Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | ImmunoGen, Seagen, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA
Antibody Drug Conjugate Pipeline
Key Takeaways from the Antibody Drug Conjugate Pipeline Report
• DelveInsight's Antibody Drug Conjugate pipeline report depicts a robust space with 180+ active players working to develop 290+ pipeline therapies for Antibody Drug Conjugate treatment.
• The leading companies working in the Antibody Drug Conjugate Market include NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others.
• Promising Antibody Drug Conjugate Pipeline Therapies in the various stages of development include Mirvetuximab Soravtansine, Datopotamab deruxtecan, Ladiratuzumab vedotin, STI-6129, MYTX-011, M1231, NBE-002, Sacituzumab Govitecan, IMGN151, IMGC936, REGN5093-M114, ASN004, TR1801-ADC, STRO-001, OBI-999, YL201, TORL-2-307-ADC, ARX788, and others.
• December 2023: Unicancer announced a drug which is named DS-8201a in the clinical trials of phase 2. Multicenter, open-label phase II trial assessing the efficacy of DS-8201a monotherapy in patients with metastatic breast cancer.
• December 2023: Daiichi Sankyo Inc. announced a drug which is named Ifinatamab Deruxtecan (I-DXd) in the clinical trials of phase 2. This study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung Cancer (ES-SCLC) who received at least 1 prior line of platinum-based chemotherapy and a maximum 3 prior lines of therapy and to investigate I-DXd anti-tumor activity in this population.
Request a sample and discover the recent advances in Antibody Drug Conjugate Drugs @ Antibody Drug Conjugate Competitive Landscape Report- https://www.delveinsight.com/report-store/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Antibody Drug Conjugate Pipeline Report provides in-depth commercial assessment of ADC drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the Antibody Drug Conjugate pipeline report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Antibody Drug Conjugate Overview
Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine an antibody specific to cancer cells with a potent cytotoxic drug. This design allows the selective delivery of the drug to cancer cells, minimizing damage to healthy tissues. The antibody component binds to antigens on the surface of cancer cells, and once bound, the ADC is internalized and the cytotoxic drug is released inside the cell, leading to cell death.
ADCs consist of three main components: the antibody, the linker, and the cytotoxic drug. The antibody ensures specificity by targeting cancer cell antigens. The linker, which can be cleavable or non-cleavable, attaches the drug to the antibody and ensures its stable delivery to the target site. The cytotoxic drug, often referred to as the payload, is typically a highly potent agent that can kill cancer cells even at low concentrations.
ADCs offer a promising approach for cancer treatment, providing the precision of targeted therapy with the potency of chemotherapy. Recent advancements in ADC technology have led to the development of several FDA-approved ADCs for various cancers, and ongoing research continues to enhance their efficacy, safety, and applicability to a broader range of malignancies.
Find out more about Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment @ Antibody Drug Conjugate Collaboration Analysis by Companies- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Antibody Drug Conjugate Pipeline Therapies and Companies
• Jiangsu Hengrui Medicine Co Ltd.: SHR-A1811
• Seagen Inc.: Ladiratuzumab Vedotin
• ImmunoGen Inc.: IMGN151
• Daiichi Sankyo: DS-6000
Antibody Drug Conjugate Pipeline Analytical Perspective
The Antibody Drug Conjugate pipeline report provides in-depth commercial assessment of Antibody Drug Conjugate drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the Antibody Drug Conjugate pipeline report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Antibody Drug Conjugate Pipeline Report Assessment
• Antibody Drug Conjugate Company Analysis
• Antibody Drug Conjugate Pipeline Therapeutic Assessment
• Antibody Drug Conjugate Pipeline Assessment
• Inactive Antibody Drug Conjugate drugs assessment
• Antibody Drug Conjugate Unmet Needs
Learn more about the emerging Antibody Drug Conjugate Competitive Landscape @ Antibody Drug Conjugate Market Drivers and Barriers, Unmet Needs- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Antibody Drug Conjugate Competitive Landscape Report
• Coverage- Global
• Antibody Drug Conjugate Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
• Antibody Drug Conjugate Companies- NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others.
• Antibody Drug Conjugate Pipeline Therapies- Mirvetuximab Soravtansine, Datopotamab deruxtecan, Ladiratuzumab vedotin, STI-6129, MYTX-011, M1231, NBE-002, Sacituzumab Govitecan, IMGN151, IMGC936, REGN5093-M114, ASN004, TR1801-ADC, STRO-001, OBI-999, YL201, TORL-2-307-ADC, ARX788, and others.
Dive deep into rich insights for new drugs for Antibody Drug Conjugate Product Developmental Activities, Visit @ Antibody Drug Conjugate Research and Development Activities- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Antibody Drug Conjugate Executive Summary
3. Antibody Drug Conjugate Overview
4. Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment
5. Antibody Drug Conjugate Competitive Landscape
6. Antibody Drug Conjugate Therapeutic Assessment
7. Antibody Drug Conjugate: Company and Product Profiles (Marketed Therapies)
8. Pfizer
9. MYLOTARG
10. Antibody Drug Conjugate: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. ADC Therapeutics
13. Zynlonta
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Seagen Inc.
17. Ladiratuzumab Vedotin
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. ImmunoGen, Inc.
21. IMGN151
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Antibody Drug Conjugate - Unmet needs
29. Antibody Drug Conjugate- Market drivers and barriers
30. Appendix
For further information on the Antibody Drug Conjugate Report @ Antibody Drug Conjugate Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Alpha Antitrypsin Market: https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-a1atd-market
• Pediatric Obesity Market: https://www.delveinsight.com/report-store/pediatric-obesity-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/carcinoid-tumor-market
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Chronic Rhinosinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Reactive Arthritis Market: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Central Serous Chorioretinopathy Market: https://www.delveinsight.com/report-store/central-serous-chorioretinopathy-market
• Hemophilia B Market: https://www.delveinsight.com/report-store/hemophilia-b-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
Contact Us:
Ankit Nigam
Marketing Manager
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antibody Drug Conjugate Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | ImmunoGen, Seagen, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA here
News-ID: 3569436 • Views: …
More Releases from DelveInsight Business Research
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market.
As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates.
The Vitiligo Pipeline report offers extensive commercial and clinical…
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome…
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape.
The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial…
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
More Releases for Drug
Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming…
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage
Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic…
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights:
* Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029
* Global and Regional Antibody Drug Conjugate Market Insight
* Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023
* Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight
* Insight On Antibody Drug Conjugates In Clinical Trials: > 550…
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
